A trial designed to see whether children with sickle cell anemia at
high risk for stroke could safely stop receiving periodic red blood cell transfusions
after a minimum of 30 months was halted last month by the National Heart,
Lung, and Blood Institute, in Bethesda, Md. Early results from the Stroke
Prevention Trial (STOP) 2 trial indicated that stopping transfusions cannot
be recommended (http://www.nhlbi.nih.gov).
Hampton T. Sickle-Cell Transfusions. JAMA. 2005;293(4):415. doi:10.1001/jama.293.4.415-b
Customize your JAMA Network experience by selecting one or more topics from the list below.